LTR Pharma (ASX:LTP) Total Operating Expense: A$10.92 Mil (TTM As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.58
View Full Analysis

What is LTR Pharma Total Operating Expense?

LTR Pharma ASX:LTP +3.57% 15 Total Operating Expense is A$10.92 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100.

LTR Pharma's Total Operating Expense for the six months ended in Dec. 2025 was A$6.14 Mil. LTR Pharma's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$10.92 Mil.

LTR Pharma Total Operating Expense Related Terms

LTR Pharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Total Operating Expense Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
0.03 1.03 1.44 6.99 7.62

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial 2.53 4.46 2.84 4.77 6.14
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$10.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of A$10.92 Mil mean?
LTR Pharma (ASX:LTP) has a Total Operating Expense of A$10.92 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Total Operating Expense too high?
LTR Pharma's current Total Operating Expense is A$10.92 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Total Operating Expense compare to VRTX and REGN?
LTR Pharma's Total Operating Expense of A$10.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on LTR Pharma and its competitors. LTR Pharma's current Total Operating Expense is A$10.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Total Operating Expense of A$10.92 Mil. The current Total Operating Expense is A$10.92 Mil. LTR Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Total Operating Expense is A$10.92 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.58
Price